Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

13.73 -0.07 (-0.51%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 915,690
Open 13.90
Bid (Size) 13.72 (500)
Ask (Size) 13.80 (100)
Prev. Close 13.80
Today's Range 13.71 - 14.11
52wk Range 5.950 - 62.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
Via The Motley Fool
Topics Lawsuit Regulatory Compliance

Performance

YTD
-74.4%
-74.4%
1 Month
+42.9%
+42.9%
3 Month
-75.4%
-75.4%
6 Month
-64.8%
-64.8%
1 Year
-74.8%
-74.8%

More News

Read More
News headline image
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces That MoonLake Immunotherapeutics Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via NewMediaWire
Topics Lawsuit
News headline image
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces That MoonLake Immunotherapeutics Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Lawsuit
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
MLTX Class Action Reminder – Robbins LLP Reminds MoonLake Immunotherapeutics Stockholders of the Opportunity to Lead the Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
News headline image
Contact Levi & Korsinsky by December 15, 2025 Deadline to Join Class Action Against MoonLake Immunotherapeutics (MLTX)
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Contact Levi & Korsinsky by December 15, 2025 Deadline to Join Class Action Against MoonLake Immunotherapeutics (MLTX)
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Bragar Eagel & Squire, P.C. Urges Investors of aTyr, Marex, Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) - December 15, 2025 Deadline to Join - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) - December 15, 2025 Deadline to Join - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics (NASDAQ: MLTX)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTX
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTX
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
MLTX LAWSUIT ALERT: Levi & Korsinsky Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
MLTX LAWSUIT ALERT: Levi & Korsinsky Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline
Via NewMediaWire
Topics Fraud Lawsuit

Frequently Asked Questions

Is MoonLake Immunotherapeutics - Class A Ordinary Shares publicly traded?
Yes, MoonLake Immunotherapeutics - Class A Ordinary Shares is publicly traded.
What exchange does MoonLake Immunotherapeutics - Class A Ordinary Shares trade on?
MoonLake Immunotherapeutics - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares?
The ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares is MLTX on the Nasdaq Stock Market
What is the current price of MoonLake Immunotherapeutics - Class A Ordinary Shares?
The current price of MoonLake Immunotherapeutics - Class A Ordinary Shares is 13.73
When was MoonLake Immunotherapeutics - Class A Ordinary Shares last traded?
The last trade of MoonLake Immunotherapeutics - Class A Ordinary Shares was at 11/28/25 01:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.